<DOC>
	<DOCNO>NCT00198367</DOCNO>
	<brief_summary>Stage IIIA non-small cell lung cancer comprise mediastinal ganglionic invasion N2 account 20 30 % NSCLCs . They almost always potentially resectable , result obtain surgery alone surgery follow chemotherapy ( CT ) and/or radiotherapy ( RT ) insufficient . The neoadjuvant approach test , randomized test exclusive CT , noncomparative test RT-CT .</brief_summary>
	<brief_title>Three Modalities Treatment Operable Resectable Stage IIIA ( T1-3 , N2 ) Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>These result justify choice study design currently suggest , test preoperative feasibility 1. chemotherapy : cisplatin-Gemzar ( arm A ) 2. chemoradiotherapy : cisplatin-navelbine-radiotherapy ( arm B ) Carboplatin-Taxol-radiotherapy ( arm C ) . The result obtain , term feasibility toxicity , make possible select optimal diagram phase III study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Operable resectable stage IIIA ( T13 , N2 ) NSCLC World Health Organization ( WHO ) performance status 1 less Severe cardiac , respiratory , renal hepatic failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>operable resectable stage IIIA ( T1-3 , N2 ) NSCLC</keyword>
</DOC>